GIOS Biostructures is a structural biology contract‑research organization that offers an end‑to‑end service from gene synthesis to high‑resolution X‑ray crystal structures. Using an automated crystallography platform, synchrotron access, and AI‑driven protein design (MESO™ platform), it provides purified proteins, membrane‑protein stabilization in nanodiscs, and fragment‑based screening to identify druggable sites for pharmaceutical and biotech clients.
Funding
Funding not disclosed
Founders
Product
Problem
Obtaining high-quality structural data for proteins, especially membrane proteins, is time‑consuming and requires multiple specialized steps—from gene design and protein production to crystallization and data analysis. Limited access to automated crystallography platforms and stable membrane protein preparations hampers rapid drug discovery and protein engineering efforts.
Solution
GIOS Biostructures provides a fully integrated structural biology contract‑research service that streamlines the entire workflow from gene to final atomic model. The company combines automated high‑throughput X‑ray crystallography, synchrotron data collection, and AI‑driven protein design to deliver purified proteins, crystal structures, and fragment‑screening results. Its proprietary MESO‑platform stabilizes membrane proteins in next‑generation nanodiscs (MESOdisc™), enabling soluble, conformationally locked targets for downstream assays. Clients receive milligram‑scale protein batches, high‑resolution structures, and data‑driven insights for druggable site identification, all through a single coordinated pipeline.
Target Audience
Primary customers are pharmaceutical companies, biotechnology firms, and academic research groups engaged in drug discovery, protein engineering, and structural biology projects.
Features
- End‑to‑end service covering gene synthesis, cloning, expression, purification, and crystallization
- Automated high‑throughput X‑ray crystallography with synchrotron access for rapid structure determination
- Small‑scale X‑ray fragment‑based screening to map druggable pockets, including cryptic sites
- AI‑powered de novo protein design and engineering via the GIOS MESO™ platform
- MESOdisc™ nanodisc technology that stabilizes membrane proteins in soluble, conformationally locked form
- Delivery of high‑quality structural models and raw diffraction data in standard formats